Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance

Ended third quarter with $24.1 million in cash and restricted cash- Expects positive fourth quarter earnings between $0.01 and $0.04 per shareTARPON SPRINGS, Fla., November 13, 2026 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) NASDAQ:ALLR, a Phase 2 clinical-stage pharmaceutical co…